Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 20/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13761091 | 0.89 | CCR1 (0.49) | CCR1CYP2C19KCNH2 | |
| SCHEMBL3464645 | 0.85 | CCR1 (0.70) | CCR1CYP2C19KCNH2 | |
| SCHEMBL3464028 | 0.82 | CCR1 (0.49) | CCR1CYP2C19KCNH2 | |
| SCHEMBL4452507 | 0.80 | CCR1 (0.71) | CCR1CYP2C19KCNH2 | |
| SCHEMBL14495077 | 0.80 | CCR1 (0.42) | CCR1 | |
| SCHEMBL4824804 | 0.79 | CCR1 (0.56) | CCR1CYP2C19KCNH2 | |
| SCHEMBL4825041 | 0.78 | CCR1 (0.44) | CCR1CYP2C19KCNH2 | |
| SCHEMBL4455328 | 0.77 | CCR1 (0.40) | CCR1 | |
| SCHEMBL4449398 | 0.76 | CCR1 (0.52) | CCR1 | |
| SCHEMBL13761267 | 0.76 | CCR1 (0.52) | CCR1CYP2C19KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576218-B2 | 4-phenylpiperdine-pyrazole CCR1 antagonists | CHEMOCENTRYX, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-7576218-B2 | 4-phenylpiperdine-pyrazole CCR1 antagonists | CHEMOCENTRYX, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-7576218-B2 | 4-phenylpiperdine-pyrazole CCR1 antagonists | CHEMOCENTRYX, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-20070088036-A1 | Piperidine derivatives and methods of use | CHEMOCENTRYX, INC. (US) | 2007-04-19 | — | — | US | disclosed |
| US-20070088036-A1 | Piperidine derivatives and methods of use | CHEMOCENTRYX, INC. (US) | 2007-04-19 | — | — | US | disclosed |
| US-20070088036-A1 | Piperidine derivatives and methods of use | CHEMOCENTRYX, INC. (US) | 2007-04-19 | — | — | US | disclosed |
| WO-2007044804-A2 | PIPERIDINE DERIVATIVES AND METHODS OF USE | CHEMOCENTRYX, INC. (US) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070088036-A1 | Piperidine derivatives and methods of use | CCR1, CCR3, CCR4 | CCR1 1/4885CYP2C19 3474/4885KCNH2 4233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.